# Pharmacokinetic/Pharmacodynamic Equivalence of MSB11455 in Healthy Subjects

> **NCT03251248** · PHASE1 · COMPLETED · sponsor: **Fresenius Kabi SwissBioSim GmbH** · enrollment: 294 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** MSB11455
- **DRUG:** Neulasta

## Key facts

- **NCT ID:** NCT03251248
- **Lead sponsor:** Fresenius Kabi SwissBioSim GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-22
- **Primary completion:** 2018-05-08
- **Final completion:** 2018-10-17
- **Target enrollment:** 294 (ACTUAL)
- **Last updated:** 2019-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03251248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03251248, "Pharmacokinetic/Pharmacodynamic Equivalence of MSB11455 in Healthy Subjects". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03251248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*